For Cytogenetic-Test Providers, the Devil's in the Interpretation of Array Results | GenomeWeb

By Justin Petrone

Laboratories that offer array-based tests for genetic abnormalities are generally satisfied with the quality of the technology platforms available, but are sometimes challenged by the interpretation of the ambiguous data that arrays can provide.

Because of this, companies targeting the clinical cytogenetics market are investing more resources in developing software tools to support their clients as they seek to determine whether variation picked up by arrays is benign or pathogenic.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.